Ardelyx Inc
Change company Symbol lookup
Select an option...
ARDX Ardelyx Inc
SNN Smith & Nephew PLC
IMKTA Ingles Markets Inc
III Information Services Group Inc
HVRRY Hannover Rueck SE
HVRRF Hannover Rueck SE
HNFSB Hanover Foods Corp
HNFSA Hanover Foods Corp
HJLI Hancock Jaffe Laboratories Inc
HHSE Hannover House Inc
Go

Health Care : Biotechnology | Small Cap ValueCompany profile

Ardelyx, Inc. is a clinical-stage biopharmaceutical company. The Company's therapeutics focuses on addressing cardiorenal and gastrointestinal (GI) diseases. It operates through the research, development and commercialization of biopharmaceutical products segment. The Company's products line includes cardiorenal portfolio and gastrointestinal portfolio. The Company's cardiorenal portfolio includes two Phase III clinical product candidates, tenapanor in Phase III clinical development for treating hyperphosphatemia in end-stage renal disease (ESRD) patients on dialysis and RDX7675 in Phase III clinical development for treating hyperkalemia in chronic kidney disease (CKD) and heart failure patients. The cardiorenal portfolio includes tenapanor, RDX7675, RDX013 and RDX011. Its gastrointestinal portfolio is led by tenapanor for the treatment of irritable bowel syndrome with constipation (IBS-C). The gastrointestinal portfolio includes tenapanor, RDX8940, RDX011 and RDX023.

Closing Price
$6.14
Day's Change
-0.01 (-0.16%)
Bid
--
Ask
--
B/A Size
--
Day's High
6.22
Day's Low
6.02
Volume
(Below Average)
Volume:
378,009

10-day average volume:
451,967
378,009

Unable to locate that news article. Back to news results

Earnings Calendar and Events Data provided by |Terms of Use| © 2019 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2019. All rights reserved.